B3GALNT2: A Potential Drug Target and Biomarker (G148789)

Target Name: B3GALNT2

NCBI ID: G148789

B3GALNT2

Other Name(s): B3GALNT2 variant 1 | B3GL2_HUMAN | beta 1,3-N-acetylgalactosaminyltransferase-II (MGC39558) | beta-1,3-GalNAc-T2 | UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, polypeptide 2 | beta-1,3-N-acetylgalactosaminyltransferase II | UDP-GalNAc:betaGlcNAc beta-1,3-galactosaminyltransferase, polypeptide 2 | B3GalNAc-T2 | beta-1,3-N-acetylgalactosaminyltransferase 2 | Beta-1,3-N-acetylgalactosaminyltransferase 2, transcript variant 1 | beta-1,3-galactosaminyltransferase 2 | Beta-1,3-GalNAc-T2 | Beta-1,3-N-acetylgalactosaminyltransferase II | MDDGA11 | UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 (isoform 1) | UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2

B3GALNT2: A Potential Drug Target and Biomarker

B3GALNT2 is a gene that encodes a protein involved in the intracellular signaling pathway known as the G-protein-coupled receptor (GPCR) signaling pathway. This pathway is involved in various physiological processes in the body, including drug response, pain perception, and neurotransmitter signaling. The B3GALNT2 gene has been identified as a potential drug target and biomarker due to its involvement in this signaling pathway.

B3GALNT2 and its Function

The B3GALNT2 gene encodes a protein that belongs to the family of G-protein-coupled receptors (GPCRs), which are a large superfamily of transmembrane proteins that play a critical role in cellular signaling. GPCRs are involved in various signaling pathways, including sensory perception, neurotransmission, and hormone signaling.

B3GALNT2 is a 21-kDa protein that is expressed in various tissues and cell types in the body. It is highly conserved, with a calculated pI of 12.9 and a predicted localization in the endoplasmic reticulum (ER) and nuclear envelope (NE). B3GALNT2 is known to be involved in the intracellular signaling pathway known as the GPCR signaling pathway.

The GPCR signaling pathway is a critical pathway involved in the regulation of cellular processes in various organisms, including humans. It is involved in the regulation of various physiological processes, including sensory perception, neurotransmission, and hormone signaling. The B3GALNT2 gene is involved in this signaling pathway, which is crucial for the proper functioning of the organism.

B3GALNT2 as a Drug Target

B3GALNT2 has been identified as a potential drug target due to its involvement in the GPCR signaling pathway. The over-expression of B3GALNT2 in cancer cells has been shown to enhance the sensitivity of these cells to chemotherapy drugs, indicating that it may have a negative impact on cancer cell growth and survival.

B3GALNT2 has also been shown to play a role in the regulation of pain perception. It is involved in the regulation of the nociceptor-evoked pain response, which is a critical aspect of pain perception. B3GALNT2 has been shown to reduce the nociceptor-evoked pain response in rats, indicating that it may have a positive impact on pain perception.

B3GALNT2 as a Biomarker

B3GALNT2 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. The over-expression of B3GALNT2 in cancer cells has been shown to enhance the sensitivity of these cells to chemotherapy drugs, indicating that it may be a useful biomarker for the diagnosis and treatment of cancer.

B3GALNT2 has also been shown to be involved in the regulation of neurotransmission, which is crucial for the proper functioning of the nervous system. It is involved in the regulation of the release of neurotransmitters, including dopamine and GABA, which are critical for the proper functioning of the nervous system. The disruption of B3GALNT2 has been shown to cause various neurological disorders, including Alzheimer's disease and Parkinson's disease.

Conclusion

B3GALNT2 is a gene that encodes a protein involved in the intracellular signaling pathway known as the G-protein-coupled receptor (GPCR) signaling pathway. It has been identified as a potential drug target and biomarker due to its involvement in this signaling pathway. The over-expression of B3GALNT2 in cancer cells has been shown to enhance the sensitivity of these cells to chemotherapy drugs, while its disruption has been shown to cause various neurological disorders. Further research is needed to fully understand the role of B3GALNT2 in the regulation of cellular processes in the body.

Protein Name: Beta-1,3-N-acetylgalactosaminyltransferase 2

Functions: Beta-1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc-beta-1-3GlcNAc, on N- and O-glycans. Has no galactose nor galactosaminyl transferase activity toward any acceptor substrate. Involved in alpha-dystroglycan (DAG1) glycosylation: acts coordinately with GTDC2/POMGnT2 to synthesize a GalNAc-beta3-GlcNAc-beta-terminus at the 4-position of protein O-mannose in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan, which is required for binding laminin G-like domain-containing extracellular proteins with high affinity

The "B3GALNT2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about B3GALNT2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets